A Closer Look: BMS Strikes First China-only Deal By In-licensing Mature CV Drug From Kyowa Hakko Kirin
This article was originally published in PharmAsia News
Executive Summary
To enrich its cardiovascular pipeline in China, BMS strikes its first “China only” deal to in-license a hypertension drug already on China’s NDRL from Kyowa Hakko Kirin.